KIRKLAND, QC, Nov. 24, 2015 /CNW Telbec/ - Ortho Regenerative Technologies Inc. ("Ortho RTi"), a Canadian orthopaedic biotechnology company, announced today that it has filed a preliminary prospectus with the securities regulatory authorities of all provinces and territories in Canada.
The non-financing prospectus was filed in connection with a proposed distribution by Manitex Capital Inc. ("Manitex") of a maximum of 1,256,127 Class "A" common shares of Ortho RTi to holders of Manitex common shares as a dividend-in-kind. The dividend would be paid on the basis of one Class "A" common share of Ortho RTi for every ten Manitex common shares which are outstanding on the record date to be fixed by the board of directors of Manitex.
Prior to the filing of the final prospectus, Ortho RTi will apply to list its Class "A" common shares on a Canadian stock exchange. Listing will be subject to Ortho RTi fulfilling all of the listing requirements of that stock exchange.
The preliminary prospectus can be found on SEDAR at www.sedar.com.
About Ortho RTi
Ortho Regenerative Technologies Inc is a Canadian orthopaedic biotechnology company dedicated to the development of medical devices to treat unmet needs in the orthopaedic market. Based on a proprietary biopolymer platform, the company is developing new regenerative treatments for soft tissue tears in the shoulder and knee as well as articular cartilage injuries, all currently with few productive options for repair.
Certain statements made herein contain forward-looking information, including statements concerning final prospectus filings, transaction terms, and the Company's intended use of the net proceeds of any offering of common shares. Although Ortho RTi believes these statements to be reasonable, the assumptions upon which they are based may prove to be incorrect. Furthermore, the forward-looking statements contained in this press release are made as at the date of this press release and Ortho RTi does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws.
SOURCE Ortho RTI
For further information: Company Contact: Steve Saviuk, President and CEO, Ortho RTi, saviuk@OrthoRTi.com, 514-782-0951